Skip to contentA
Adaptimmune Therapeutics PLC
A
ADAPYAdaptimmune Therapeutics PLC Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.42M$1.42Mderived−5.7% vs Q4 2020 Net Income-$38.86M-$38.86MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$42,864,000N/M Operating Cash Flowderived$133,928,000N/M Free Cash Flowderived$129,912,000N/M Margins · derivedOperating margin-3025.0%−527.4 pt vs Q4 2020
Net margin-2742.3%−304.7 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 14, 2022 · 73 d after period end